Table 3.
Performance of 18F-FDOPA in discriminating recurrence from post-therapeutic effects
| Authors | Year | Patients (#) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) | Cut-off |
|---|---|---|---|---|---|---|---|---|
| Zaragori et al. | 2020 | 51 | 97.1 | 94.1 | NA | NA | 96 | T/S > 1 |
| Youland et al. | 2018 | 13 | 82 | 50 | NA | NA | NA | T/N > 2.0 |
| Karunanithi et al.a | 2014 | 30 | 100 | 87.5 | NA | NA | 96 | T/S > 0.6 |
| Karunanithi et al.a | 2013 | 35 | 100 | 88.9 | NA | NA | 97.1 | NA (visual) |
| Herrmann et al. | 2013 | 110 | 85.2 | 72.4 | 89.6 | 63.4 | 81.8 | T/N > 1.81 |
| Karunanithi et al.a | 2013 | 28 | 100 | 85.7 | NA | NA | 96.4 | T/N > 1.3 |
NA Not available, NPV Negative predictive value, PPV Positive predictive value, T/N Tumor uptake divided by normal brain uptake, T/S Tumor uptake divided by striatum uptake
a: the results of these studies are based on the same patient population